がん患者の運動器疾患の診かた

出版社： 中外医学社
著者：
発行日： 2019-11-01
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784498054820
電子書籍版： 2019-11-01 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,840 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,840 円(税込)

購入する

商品紹介

「がんロコモ」とは，「がんに関連した運動器障害によって移動能力が低下した状態」である．がん治療の進歩に伴い，「がんロコモ」に対応し，患者の運動器という観点からがん診療に取り組むことが望まれている．運動器の機能を維持・改善することは，がん患者が自身の力で動くため，生活するため，治療を受けるために極めて重要であり，本書は，このがん患者の運動器疾患についてまとめた新しいアプローチの書籍となっている．

目次

  • ch. 1　がん患者の運動器疾患　─がんロコモとは─
    　1　がんとロコモティブシンドローム
    　2　がんロコモの概念　─がんロコモの目指すもの─　
    　3　がんロコモの分類
    　4　がん患者の運動機能評価

    ch. 2　がんロコモの原因と対策
    　2―1　がん治療に関連する運動器疾患
    　2―2　運動器疾患としての骨転移
    　2―3　がん患者と良性運動器疾患

    ch. 3　がん患者の社会復帰
    　1　がん患者の在宅支援　─がんロコモ対策が果たす役割─
    　2　がん患者の運動器管理と医療連携　─ 一般整形外科医によるがんロコモ対策─
    　3　がん患者の就労と運動器管理　─就労支援とがんロコモ─　

    ch. 4　キャンサーボードと骨転移外来
    　1　がん診療拠点病院とキャンサーボード　─がんロコモにおける役割─　
    　2　骨転移キャンサーボード　─立ち上げから運営まで─
    　3　骨転移キャンサーボードの実際　─その内容と結果─　
    　4　骨転移外来　─外来でできるがんロコモ─

    ch. 5　がんロコモへの対応の具体例（セルフチェック）
    　問題
    　解答と解説

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

ch. 1 がん患者の運動器疾患 - がんロコモとは -

P.16 掲載の参考文献
(1) 全国がん罹患モニタリング集計 2006-2008年生存率報告. 国立がん研究センターがん対策情報センター ; 2016.
 
(2) 眞鍋淳. がん骨転移に対する集学的治療-骨転移Cancer BoardとBone Management-. 癌の臨床. 2012 ; 58 : 43-50.
Medical*Online
(3) 中田英二, 杉原進介, 菅原敬文, 他. 骨転移診療システム 脊椎転移による麻痺や廃用症候群予防を目的とした取り組み. 関節外科. 2016 ; 35 : 374-87.
Medical*Online
(4) Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014 ; 3 : 1359-67.
PubMed
(5) 日本臨床腫瘍学会, 編. 骨転移診療ガイドライン. 東京 : 南江堂 ; 2015.
 
(6) 若林秀隆. サルコペニアとリハビリテーション. Loco Cure. 2017 ; 3 : 24-8.
Medical*Online
(7) 深貝隆志. 前立腺癌に対するホルモン療法後の骨粗鬆症予防. 泌尿器外科. 2017 ; 30 : 1489-95.
Medical*Online
(8) 高橋俊二. 乳癌患者における骨転移, 骨合併症の治療. White. 2018 ; 6 : 35-41.
Medical*Online
(9) 骨粗鬆症の予防と治療ガイドライン作成委員会, 編. 骨粗鬆症の予防と治療ガイドライン 2015年版. 東京 : ライフサイエンス出版 ; 2015.
 
(10) 日本がんサポーティブケア学会, 編. JASCCがん支持医療ガイドシリーズ. がん薬物療法に伴う末梢神経障害のマネジメントの手引き. 東京 : 金原出版 ; 2017.
 
P.23 掲載の参考文献
(1) 日本整形外科身体障害委員会・日本リハビリテーション医学会評価基準委員会. 関節可動域表示ならびに測定法. リハ医. 1973 ; 11 : 127-32.
 
(2) 日本整形外科学会身体障害委員会. 関節可動域表示ならびに測定法 (平成7年2月改訂). 日整会誌. 1995 ; 69 : 240-50.
 
(3) 中村利孝, 松野丈夫, 監修. 標準整形外科. 第13版. 東京 : 医学書院 ; 2016. p.934-41.
 
(4) Hislop HJ, Avers D, Brown M, et al. 新・徒手筋力検査法. 原著第9版. 東京 : 協同医書出版社 ; 2014.
 
(5) 中村利孝, 松野丈夫, 監修. 標準整形外科. 第13版. 東京 : 医学書院 ; 2016. p.942-3.
 
(6) Common Toxicity Criteria, Version 2.0 Publish Date April 30, 1999. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf (JCOGホームページ http://www.jcog.jp/)
 
(7) Frankel HL, Hancock DO, Hyslop G, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. Paraplegia. 1969 ; 7 : 179-92.
PubMed
(8) 福田文雄, 植田尊善. 改良Frankel分類による頚髄損傷の予後予測. リハ医. 2001 ; 38 : 29-33.
 
(9) Maynard FM. International standards for neurological and functional classification of spinal cord injury. Spinal Cord. 1997 ; 35 : 266-74.
PubMed
(10) Mahoney FI, Barthel DW. Functional evaluation : the Barthel Index. Md State Med J. 1965 ; 14 : 61.
PubMed

ch. 2 がんロコモの原因と対策

P.32 掲載の参考文献
(1) Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol. 2010 ; 28 : 5132-9.
PubMed
(2) Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet. 2011 ; 377 : 813-22.
PubMed
(3) Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011 ; 29 : 1125-32.
PubMed
(4) Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006 ; 440 : 692-6.
PubMed
(5) Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011 ; 470 : 548-53.
PubMed
(6) Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hypercalcemia in adult T-cell leukemia : overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002 ; 99 : 634-40.
PubMed
(7) van der Heijden L, Dijkstra PDS, Blay JY, et al. Giant cell tumour of bone in the denosumab era. Eur J Cancer. 2017 ; 77 : 75-83.
PubMed
(8) Matsumoto T, Abe M. TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone. 2011 ; 48 : 129-34.
 
(9) Takeuchi K, Abe M, Hiasa M, et al. TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One. 2010 ; 5 : e9870.
 
(10) Iwasaki H, Suda T. Cancer stem cells and their niche. Cancer Sci. 2009 ; 100 : 1166-72.
PubMed
(11) Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007 ; 130 : 811-23.
PubMed
(12) Miyauchi Y, Sato Y, Kobayashi T, et al. HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A. 2013 ; 110 : 16568-73.
 
(13) Morita M, Sato Y, Iwasaki R, et al. Selective estrogen receptor modulators suppress HIF1α protein accumulation in mouse osteoclasts. PLoS One. 2016 ; 11 : e0165922.
 
(14) Sato Y, Miyauchi Y, Yoshida S, et al. The vitamin D analogue ED71 but not 1,25 (OH) 2D3 targets HIF1α protein in osteoclasts. PLoS One. 2014 ; 9 : e111845.
 
(15) Tando T, Sato Y, Miyamoto K, et al. HIF1α is required for osteoclast activation and bone loss in male osteoporosis. Biochem Biophys Res Commun. 2016 ; 470 : 391-6.
 
(16) Sato Y, Tando T, Morita M, et al. Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis. Biochem Biophys Res Commun. 2017 ; 482 : 1430-6.
PubMed
(17) Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009 ; 301 : 513-21.
PubMed
P.37 掲載の参考文献
(1) Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity : a critical analysis. CA Cancer J Clin. 2013 ; 63 : 419-37.
PubMed
(2) 荒川和, 鳥越一, 葛巻直, 他. 抗がん剤による末梢神経障害の特徴とその作用機序. 日緩和医療薬誌. 2011 ; 4 : 1-13.
 
(3) 河野豊, 永田博. [薬物と神経筋障害 : 診断と治療の進歩] 薬物による神経障害 末梢神経障害の機序. 日内会誌. 2007 ; 96 : 1585-90.
 
(4) Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity : changes in axonal excitability precede development of neuropathy. Brain. 2009 ; 132 (Pt 10) : 2712-23.
 
(5) Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy : a systematic review and meta-analysis. Pain. 2014 ; 155 : 2461-70.
PubMed
(6) Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016 ; 34 : 3014-22.
PubMed
(7) JCOG (Japan Clinical Oncology Group) 有害事象共通用語規準 v5.0 日本語訳JCOG版. http://www.jcog.jp.
 
(8) Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011 ; 34 : E10-20.
PubMed
(9) Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst. 2011 ; 16 : 228-36.
PubMed
(10) Smith EM, Cohen JA, Pett MA, et al. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs. 2010 ; 33 : 173-83.
PubMed
(11) Cavaletti G, Frigeni B, Lanzani F, et al. The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity : comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007 ; 12 : 210-5.
PubMed
(12) Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006 ; 11 : 135-41.
PubMed
(13) Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOGNtx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003 ; 13 : 741-8.
 
(14) Kuroi K, Shimozuma K, Ohashi Y, et al. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer. 2009 ; 17 : 1071-80.
PubMed
(15) Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 ; 27 : 3109-16.
 
(16) Vaidyanathan G, Groman A, Wilding G, et al. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. Oncology. 2010 ; 79 : 67-71.
PubMed
(17) Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers : American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 ; 32 : 1941-67.
 
(18) Hanai A, Ishiguro H, Sozu T, et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy : prospective self-controlled trial. J Natl Cancer Inst. 2018 ; 110 : 141-8.
 
(19) Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial. JAMA. 2013 ; 309 : 1359-67.
PubMed
P.44 掲載の参考文献
(1) 日本リハビリテーション医学会, 編. リハビリテーション医学・医療用語集. 第8版. 東京 : 文光堂 ; 2019.
 
(2) Dietz JH. Rehabilitation Oncology. New York : John Wiley & Sons ; 1981.
 
(3) ロコモチャレンジ! 推進協議会 : ロコモを知ろう. https://locomo-joa.jp/locomo
 
P.50 掲載の参考文献
(1) Inui A. Cancer anorexia-cachexia syndrome : current issues in research and management. CA Cancer J Clin. 2002 ; 52 : 72-91.
PubMed
(2) Huang DD, Chen XX, Chen XY, et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer : a prospective study. J Cancer Res Clin Oncol. 2016 ; 142 : 2347-56.
PubMed
(3) Allgayer H, Owen RW, Nair J, et al. Short-term moderate exercise programs reduce oxidative DNA damage as determined by high-performance liquid chromatography-electrospray ionization-mass spectrometry in patients with colorectal carcinoma following primary treatment. Scand J Gastroenterol. 2008 ; 43 : 971-8.
PubMed
(4) Simonsen C, de Heer P, Bjerre ED, et al. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology : a meta-analysis. Ann Surg. 2018 ; 268 : 58-69.
PubMed
(5) Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev. 2017 ; 6 : CD012020.
PubMed
(6) 右高沙妃, 柳澤卓也, 帆澪子, 他. 消化器がん術後合併症の有無が身体機能に与える影響. 第7回日本がんリハビリテーション研究会. 2018 ; S54.
 
(7) Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982 ; 14 : 377-81.
PubMed
(8) 日本がんリハビリテーション研究会, 編. がんのリハビリテーションベストプラクティス. 東京 : 金原出版 ; 2015. p.244-5.
 
(9) ロコモ チャレンジ! 推進協議会. ロコモパンフレット 2015年度版.
 
(10) 三浦靖史, 井上順一郎. 化学療法・放射線療法中のリハビリテーション. J Clin Rehabil. 2015 ; 24 : 26-35.
 
(11) 日本リハビリテーション医学会. がんのリハビリテーション診療ガイドライン. 第2版. 東京 : 金原出版 ; 2019. p.202-10.
 
(12) 日本リハビリテーション医学会. がんのリハビリテーション診療ガイドライン. 第2版. 東京 : 金原出版 ; 2019. p.263-8.
 
(13) Eastern Cooperative Oncology Group : ECOG performance status. http://ecog-acrin.org/resources/ecog-performance-status.
 
P.56 掲載の参考文献
(1) 日本整形外科学会骨軟部腫瘍委員会, 編. 全国骨腫瘍登録一覧表 平成27年度. 国立がんセンター ; 2015.
 
(2) Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012 ; 4 : 87-93.
 
(3) 森脇昭介, 万代光一, 山上啓太郎. 癌の骨髄転移の病理形態と問題点. 病理と臨床. 1999 ; 17 : 28-34.
Medical*Online
(4) がんの統計 '18 CANCER STATISTICS IN JAPAN-2018. https://ganjoho.jp/data/reg_stat/statistics/brochure/2018/cancer_statistics_2018_app_J.pdf
 
(5) Hernandez RK, Wade SW, Reich A, et al. Incidence of bone metastases in patients with solid tumors : analysis of oncology electronic medical records in the United States. BMC Cancer. 2018 ; 18 : 44.
PubMed
(6) Liede A, Jerzak KJ, Hernandez RK, et al. The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Res Treat. 2016 ; 156 : 587-95.
PubMed
(7) Oka H, Kondoh T, Seichi A, et al. Incidence and prognostic factors of Japanese breast cancer patients with bone metastasis. J Orthop Sci. 2006 ; 11 : 13-9
 
(8) Plunkett TA, Rubens RD. Clinical features and prognosis of bone metastases. In : Jasmin C, Coleman RE, Coia LR, et al, eds. Textbook of bone metastases. West Sussex : Wiley ; 2005. p.66-75.
 
(9) Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014 ; 3 : 1359-67.
PubMed
(10) Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 ; 21 : 3150-7.
 
(11) Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 ; 48 : 3082-92.
PubMed
P.61 掲載の参考文献
(1) Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989 ; 8 : 98-101.
PubMed
(2) Croucher PI, McDonald MM, Martin TJ. Bone metastasis : the importance of the neighbourhood. Nat Rev Cancer. 2016 ; 16 : 373-86.
PubMed
(3) Sims NA, Gooi JH. Bone remodeling : multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 2008 ; 19 : 444-51.
 
(4) Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res. 1993 ; 8 Suppl 2 : S565-72.
 
(5) Wang H, Yu C, Gao X, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015 ; 27 : 193-210.
 
(6) Ottewell PD, Wang N, Brown HK, et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res. 2014 ; 20 : 2922-32.
PubMed
(7) Lawson MA, McDonald MM, Kovacic N, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015 ; 6 : 8983.
PubMed
(8) Johnson RW, Suva LJ. Hallmarks of bone metastasis. Calcif Tissue Int. 2018 ; 102 : 141-51.
PubMed
(9) Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 2011 ; 13 : R106.
PubMed
(10) Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003 ; 349 : 2483-94.
PubMed
(11) Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005 ; 5 : 21-8.
PubMed
(12) Park SH, Keller ET, Shiozawa Y. Bone marrow microenvironment as a regulator and therapeutic target for prostate cancer bone metastasis. Calcif Tissue Int. 2018 ; 102 : 152-62.
PubMed
(13) Hashimoto K, Ochi H, Sunamura S, et al. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc Natl Acad Sci U S A. 2018 ; 115 : 2204-9.
PubMed
P.67 掲載の参考文献
(1) Solberg A, Bremnes RM. Metastatic spinal cord compression : diagnostic delay, treatment, and outcome. Anticancer Res. 1999 ; 19 : 677-84.
 
(2) Loblaw DA, Perry J, Chambers A, et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression : the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol. 2005 ; 23 : 2028-37.
 
(3) National Collaborating Centre for Cancer (UK). Metastatic spinal cord compression : diagnosis and management of patients at risk of or with metastatic spinal cord compression. Cardiff (UK) : National Collaborating Centre for Cancer (UK) ; 2008.
PubMed
(4) van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer : a systematic review of the past 40 years. Ann Oncol. 2007 ; 18 : 1437-49.
 
(5) Coleman RE. Skeletal complications of malignancy. Cancer. 1997 ; 80 (8 Suppl) : 1588-94.
 
(6) Falk S, Dickenson AH. Pain and nociception : mechanisms of cancer-induced bone pain. J Clin Oncol. 2014 ; 32 : 1647-54.
 
(7) Middlemiss T, Laird BJ, Fallon MT. Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol). 2011 ; 23 : 387-92
 
(8) 中田英二, 杉原進介, 菅原敬文, 他. 脊椎転移の早期診断・早期治療による麻痺予防とRT の治療成績. 整外最小侵襲術誌. 2017 ; 84 : 29-41.
Medical*Online
(9) 中田英二, 杉原進介, 尾崎敏文. 骨転移診療システム-脊椎転移による麻痺や廃用症候群予防を目的とした取り組み. 関節外科. 2016 ; 35 : 38-51.
 
(10) 中田英二, 杉原進介, 尾崎敏文. 脊椎転移による麻痺を予防する取り組み. 腫瘍内科. 2016 ; 18 : 362-70.
 
(11) 中田英二, 杉原進介, 尾崎敏文. 麻痺の無い脊椎の骨関連事象 (SRE) に対するRTの治療成績. 整・災外. 2017 ; 66 : 921-5.
Medical*Online
(12) Nakata E, Sugihara S, Kataoka M, et al. Early response assessment of palliative conventional radiotherapy for painful uncomplicated vertebral bone metastases. J Orthop Sci. 2018 ; 23 : 912-7.
PubMed
(13) Nakata E, Sugihara S, Kataoka M, et al. Early response assessment of re-ossification after palliative conventional radiotherapy for vertebral bone metastases. J Orthop Sci. 2019 ; 24 : 332-6.
PubMed
(14) 中西一夫, 射場英明, 加納健司, 他. 転移性脊椎腫瘍に対する最小侵襲脊椎固定術 (MISt) を用いたリエゾン治療. 整・災外. 2014 ; 57 : 1557-63.
 
(15) 日本臨床腫瘍学会. 骨転移ガイドライン. 東京 : 南江堂 ; 2015. p.13.
 
(16) 腰痛患者が初診した場合に必要とされる診断の手順は. In : 腰痛診療ガイドライン策定委員会. 腰痛診療ガイドライン 2019. 改訂第2版. 東京 : 南江堂 ; 2019. p.22-3.
 
P.74 掲載の参考文献
(1) Yang HL, Liu T, Wang XM, et al. Diagnosis of bone metastaseis : a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011 ; 21 : 2604-17.
 
(2) Wu LM, Gu HY, Zheng J, et al. Diagnostic value of whole-body magnetic resonance imaging for bone metastases : a systematic review and meta-analysis. J Magn Reson Imaging. 2011 ; 34 : 128-35.
PubMed
(3) Yonou H, Aoyagi Y, Kanomata N, et al. Prostete-specific antigen induces osteoplatic changes by an autonomous mechanism. Biochem Biophys Res Commun. 2001 ; 289 : 1082-7.
 
(4) 山口岳彦. 脊椎転移の臨床病理学的特徴-画像診断の信頼性を中心に. 整形外科. 2010 ; 61 : 893-7.
 
(5) Stemheim A, Glladi O, Gortsak Y, et al. Pathological fracture risk assessment in patients with femoral metastases using CT-based finite element methods. A retrospective clinical study. Bone. 2018 ; 110 : 215-20.
 
(6) Villa-Camacho JC, Iyoha-Bello O, Bherouzi S, et al. Computed tomography-based rigidity analysis : a review of the approach in preclinical and clinical studies. Bonekey Rep. 2014 ; 3 : 587.
PubMed
(7) Salvatore G, Berton A, Glambini H, et al. Biomechanical effects of metastasis in the osteoporotic lumber spine : a finite element analysis. BMC Musculoskelet Disord. 2018 ; 19 : 38.
 
(8) Louchrey GJ, Collins CD, Todd SM, et al. Magnetic resonance imaging in the management of suspected spinal canal disease in patients with known malignangcy. Clin Radiol. 2000 ; 55 : 849-55.
PubMed
(9) Oshima K, Hashimoto N, Sotobori T, et al. New magnetic resonance imaging features predictive for post-treatment ambulatory function : imaging analysis of metastatic spinal cord compression. Spine (Phila Pa 1976). 2016 ; 41 : E422-9.
PubMed
P.82 掲載の参考文献
(1) Galasko CSB. 4 Development t of skeletal metastases. In : Galasko CSB. Skeletal metastases. London : Butterworths ; 1986. p.22-51.
 
(2) Yamaguchi T, Tamai K, Yamato M, et al. Intertrabecular pattern of tumors metastatic to bone. Cancer. 1996 ; 78 : 1388-94.
PubMed
(3) Yamaguchi T. Intertrabecular vertebral metastases : metastases only detectable on MR imaging. Semin Musculoskelet Radiol. 2001 ; 5 : 171-5.
PubMed
(5) 森脇昭介. 骨転移総論. In : 森脇昭介. 骨転移の病理-基礎と臨床のはざまで-. 東京. 杏林書院 ; 2007. p.22-127.
 
(6) 山口岳彦. 脊椎転移の臨床病理学的特徴 : 画像診断の信頼性を中心に. 整形外科. 2010 ; 61 : 893-7.
 
(8) 森脇昭介. 男性器腫瘍の骨転移. In : 森脇昭介. 骨転移の病理-基礎と臨床のはざまで-. 東京 : 杏林書院 ; 2007. p.261-75.
 
(9) 内田淳正. 2 病的骨折と痛み. In : 松本俊夫, 他編. 癌と骨病変. 東京 : メディカルレビュー社 ; 2004. p.105-10.
 
(10) Yamaguchi T, Suzuki S, Ishiiwa H, et al. Schmorl's node developing in the lumbar vertebra affected with metastatic carcinoma : correlation Magnetic Resonance imaging with histological findings. Spine. 2003 ; 28 : E503-5.
 
(11) 山口岳彦. 第10章 骨関節. In : 吉野正, 他編. カラーアトラス病理組織の見方と鑑別診断. 6版. 東京 : 医歯薬出版 ; 2018. p.507-36.
 
()4 山口岳彦. 転移性骨腫瘍診断の病理と画像所見. 臨床画像. 2001 ; 17 (増刊) : 115-20.
 
()7 森脇昭介. 泌尿器系腫瘍の骨転移. In : 森脇昭介. 骨転移の病理-基礎と臨床のはざまで-. 東京. 杏林書院 ; 2007. p.249-60.
 
P.87 掲載の参考文献
(1) 日本臨床腫瘍学会, 編. 骨転移診療ガイドライン. 東京 : 南江堂 ; 2015. p.22-3.
 
(2) 日本リハビリテーション医学会, がんのリハビリテーションガイドライン策定委員会, 編. がんのリハビリテーションガイドライン. 東京 : 金原出版 ; 2013. p.91.
 
(3) Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease : an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010 ; 35 : E1221-9.
 
(4) Morris JM, Lucas DB, Bresler B, et al. Role of the trunk in stability of the relieving the pressure on the lumbar intervertebral discs. J Bone Joint Surg Am. 1961 ; 43 : 327-51.
 
(5) Bartelink DL. The role of abdominal pressure in discs. J Bone Joint Surg Br. 1957 ; 39 : 718-25.
PubMed
(6) Mirels H. Metastatic disease in long bones : a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop. 1989 ; 249 : 256-64.
 
(7) Van der Linden YM, Dijkstra PD, Kroon HM, et al. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br. 2004 ; 86 : 566-73.
PubMed
P.94 掲載の参考文献
(1) Rajani R, Quinn RH. Pathologic Fractures. In : Tornetta Iii P, Ricci WM, Court-Brown CM, et al, ed. Rockwood and Green's Fractures in Adults, 9th ed. Wolters Kluwer ; 2019.
 
(2) 日本臨床腫瘍研究グループ : ECOG のPerformance Status (PS) の日本語訳. http://www.jcog.jp/doctor/tool/C_150_0050.pdf
 
(3) Bunting RW, Boublik M, Blevins FT, et al. Functional outcome of pathologic fracture secondary to malignant diseases in a rehabilitation hospital. Cancer. 1992 ; 69 : 98-102.
 
(4) Katzer A, Meenen NM, Grabbe F, et al. Surgery of skeletal metastases. Arch Orthop Trauma Surg. 2002 ; 122 : 251-8.
PubMed
(5) Mirels H. Metastatic disease in long bones : a proposed scoring system for diagnosing impending pathological fractures. Clin Orthop Relat Res. 1989 ; 249 : 256-65.
 
(6) Van der Linden YM, Dijkstra PD, Kroon HM, et al. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br. 2004 ; 86 : 566-73.
PubMed
(7) Howard EL, Shepherd KL, Cribb G, et al. The validity of the Mirels score for predicting impending pathological fractures of the lower limb. Bone Joint J. 2018 ; 100-B (8) : 1100-5.
PubMed
(8) Willeumier JJ, van de Sande MAJ, van der Wal RJP, et al. Trends in the surgical treatment of pathological fractures of the long bones : based on aquestionnaire among members of the Dutch Orthopaedic Society and the European Musculo-Skeletal Oncology Society (EMSOS). Bone Joint J. 2018 ; 100-B (10) : 1392-8.
 
(9) Araki N, Chuman H, Matsunobu T, et al. Factors associated with the decision of operative procedure for proximal femoral bone metastasis : questionnaire survey to institutions participating the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. J Orthop Sci. 2017 ; 22 : 938-45.
 
(10) Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014 ; 3 : 1359-67.
PubMed
(11) Brown RK, Pelker RR, Friedlaender GE, et al. Postfracture radiation effects on the biomechanical and histologic parameters of fracture healing. J Orthop Res. 1991 ; 9 : 876-82.
PubMed
(12) Gainor BJ, Buchert P. Fracture healing in metastatic bone disease. Clin Orthop. 1983 ; 178 : 297-302.
PubMed
(13) Weber KL, O'Connor MI. Operative treatment of long bone metastases : focus on the femur. Clin Orthop. 2003 ; (415 Suppl) : S276-8.
 
(14) Yazawa Y, Frassica FJ, Chao EY, et al. Metastatic bone disease : a study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop. 1990 ; 251 : 213-9.
PubMed
P.101 掲載の参考文献
(1) 片桐浩久. 転移性骨腫瘍の手術. In : 岩瀬哲, 他編. 運動器マネジメントが患者の生活を変える! がんの骨転移ナビ. 東京 : 医学書院 ; 2016. p.35-42.
 
(2) 大隈知威. 長管骨骨転移の治療. In : 大森まいこ, 他編. 骨転移の診療とリハビリテーション. 東京 : 医歯薬出版 ; 2014. p.147-56.
 
(3) 日本臨床腫瘍学会, 編. 骨転移診療ガイドライン. 東京 : 南江堂 ; 2015.
 
(4) Patil CG, Lad SP, Santarelli J, et al. National inpatient complications and outcomes after surgery for spinal metastasis from 1993-2002. Cancer. 2007 ; 110 : 625-30.
PubMed
(5) Yokogawa N, Murakami H, Demura S, et al. Perioperative complications of total en bloc spondylectomy : adverse effects of preoperative irradiation. PLoS One. 2014 ; 9 : e98797
PubMed
(6) Yao KC, Boriani S, Gokaslan ZL, et al. En bloc spondylectomy for spinal metastases : a review of techniques. Neurosurg Focus. 2003 ; 15 : E6
PubMed
(7) Janssen SJ, Kortlever JTP, Ready JE, et al. Complications after surgical management of proximal femoral metastasis : a retrospective study of 417 patients. J Am Acad Orthop Surg. 2016 ; 24 : 483-94
 
(8) Finstein JL, King JJ, Fox EJ, et al. Bipolar proximal femoral replacement prostheses for musculoskeletal neoplasms. Clin Orthop Relat Res. 2007 ; 459 : 66-75.
PubMed
(9) Khattak MJ, Ashraf U, Nawaz Z, et al. Surgical management of metastatic lesions of proximal femur and the hip. Ann Med Surg (Lond). 2018 ; 36 : 90-5.
PubMed
P.114 掲載の参考文献
(1) Oshima K, Hashimoto N, Sotobori T, et al. New magnetic resonance imaging features predictive for post-treatment ambulatory function : imaging analysis of metastatic spinal cord compression. Spine. 2016 ; 41 : E422-9.
PubMed
(2) Tateiwa D, Oshima K, Nakai T, et al. Clinical outcomes and significant factors in the survival rate after decompression surgery for patients who were non-ambulatory due to spinal metastases. J Orthop Sci. 2019 ; 24 : 347-52.
PubMed
P.119 掲載の参考文献
(1) Aebi M. Spinal metastasis in the elderly. Eur Spine J. 2003 ; 12 Suppl 2 : S202-13.
 
(2) 石井賢, 有薗剛, 蜂谷裕道, 他. 手術手技シリーズ 最小侵襲脊椎安定術 (MISt). Bone Joint Nerve. 2014 ; 4 : 541-6.
 
(3) Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 2005 ; 30 : 2186-91.
PubMed
(4) Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014 ; 3 : 1359-67.
PubMed
(5) Tomita K, Kawahara N, Kobayashi T, et al. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001 ; 26 : 298-306.
PubMed
(6) Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score : an analysis of reliability and validity from the spine oncology study group. J Clin Oncol. 2011 ; 29 : 3072-7.
 
(7) Murakami H, Kawahara N, Demura S, et al. Perioperative complications and prognosis for elderly patients with spinal metastases treated by surgical strategy. Orthopedics. 2010. 33. doi : 10.3928/01477447-20100129-10.
 
(8) Arrigo RT, Kalanithi P, Cheng I, et al. Charlson score is a robust predictor of 30-day complications following spinal metastasis surgery. Spine (Phila Pa 1976). 2011 ; 36 : E1274-80.
PubMed
(9) 磯貝宜広, 八木満, 西村空也, 他. 転移性脊椎腫瘍に対する姑息的手術の周術期合併症発生率とリスク因子の検討. Spine Res. 2018 ; 9 : 701.
 
(10) Luksanapruksa P, Buchowski JM, Zebala LP, et al. Perioperative Complications of Spinal Metastases Surgery. Clin Spine Surg. 2017 ; 30 : 4-13.
PubMed
(11) 磯貝宜広, 松本守雄, 石井賢. 【低侵襲脊椎手術の合併症とRevision Surgery】 経皮的椎弓根スクリュー (PPS) を用いたMISt手技, MIS-TLIFの合併症と対策, Revision. 整外最小侵襲術誌. 2016 ; 21-2.
 
(12) Hikata T, Isogai N, Shiono Y, et al. A retrospective cohort study comparing the safety and efficacy of minimally invasive versus open surgical techniques in the treatment of spinal metastases. Clin Spine Surg. 2017 ; 30 : E1082-7.
PubMed
(13) 磯貝宜広, 船尾陽生, 前田祥宏, 他. 転移性脊椎腫瘍に対する姑息的後方除圧固定術の医療費-OPEN法とMIStとの比較研究-. Presented at the 第21回日本低侵襲脊椎外科学会学術集会. 2018.
 
(14) Funao H, Ishii K, Momoshima S, et al. Surgeons' exposure to radiation in single- and multi-level minimally invasive transforaminal lumbar interbody fusion ; a prospective study. PLoS One. 2014 ; 9 : e95233.
PubMed
(15) Sponseller P. The S2 portal to the ilium. Semin Spine Surg. 2007 ; 2 : 83-7.
 
(16) 船尾陽生, 磯貝宜広, 笹生豊, 他. S2 alar-iliac (S2AI) screw法のMIStへの応用 (特集最小侵襲脊椎安定術MIStの最前線). 整外最小侵襲術誌. 2018 : 69-79.
 
(17) Tomita K, Kawahara N, Baba H, et al. Total en bloc spondylectomy for solitary spinal metastases. Int Orthop. 1994 ; 18 : 291-8.
PubMed
(18) Ishii T, Murakami H, Demura S, et al. Invasiveness reduction of recent total en bloc spondylectomy : assessment of the learning curve. Asian Spine J. 2016 ; 10 : 522-7.
PubMed
(19) 磯貝宜広, 船尾陽生, 杉本真樹, 他. MR技術の脊椎手術への応用の実際. Presented at the 第21回日本低侵襲脊椎外科学会学術集会. 2018.
 
(20) 磯貝宜広, 船尾陽生, 石井賢. がん治療における脊椎外科の役割-転移性脊椎腫瘍を中心に-. 整・災外. 2019 ; 62 : 895-900.
 
P.125 掲載の参考文献
(1) Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer : a randomised trial. Lancet. 2005 ; 366 : 643-8.
PubMed
(2) Chi JH, Gokaslan Z, McCormick P, et al. Selecting treatment for patients with malignant epidural spinal cord compression-does age matter? : results from a randomized clinical trial. Spine (Phila Pa 1976). 2009 ; 34 : 431-5.
PubMed
(3) George R, Jeba J, Ramkumar G, et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev. 2015 ; CD006716.
PubMed
(4) Loblaw DA, Perry J, Chambers A, et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression : the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol. 2005 ; 23 : 2028-37.
 
(5) Metastatic spinal cord compression in adults : risk, assessment, diagnosis and management. https://www.nice.org.uk/guidance/cg75/
 
(6) Tsukada Y, Nakamura N, Ohde S, et al. Factors that delay treatment of symptomatic metastatic extradural spinal cord compression. J Palliat Med. 2015 ; 18 : 107-13.
PubMed
(7) Agarawal JP, Swangsilpa T, van der Linden Y, et al. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol). 2006 ; 18 : 747-60.
PubMed
(8) Rades D, Lange M, Veninga T, et al. Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2011 ; 79 : 524-30.
PubMed
(9) Maranzano E, Trippa F, Casale M, et al. 8 Gy single-dose radiotherapy is effective in metastatic spinal cord compression : results of a phase III randomized multicentre Italian trial. Radiother Oncol. 2009 ; 93 : 174-9.
PubMed
(10) Sorensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy : a randomised trial. Eur J Cancer. 1994 ; 30A : 22-7.
PubMed
(11) Maranzano E, Latini P, Beneventi S, et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. Am J Clin Oncol. 1996 ; 19 : 179-83.
 
(12) Nieder C, Grosu AL, Andratschke NH, et al. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys. 2006 ; 66 : 1446-9.
PubMed
(13) van der Linden YM, Kroon HM, Dijkstra SP, et al. Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions : results from a randomised trial. Radiother Oncol. 2003 ; 69 : 21-31.
PubMed
(14) Groenen KH, Pouw MH, Hannink G, et al. The effect of radiotherapy, and radiotherapy combined with bisphosphonates or RANK ligand inhibitors on bone quality in bone metastases. A systematic review. Radiother Oncol. 2016 ; 119 : 194-201.
PubMed
(15) Koswig S, Budach V. Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol. 1999 ; 175 : 500-8.
 
(16) Kaasa S, Brenne E, Lund JA, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. Radiother Oncol. 2006 ; 79 : 278-84.
PubMed
(17) Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 ; 97 : 798-804.
PubMed
(18) Price P, Hoskin PJ, Easton D, et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986 ; 6 : 247-55.
PubMed
(19) Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018 ; 126 : 547-57.
 
P.134 掲載の参考文献
(1) Holsheimer J, den Boar JA, Struijk JJ, et al. MR assessment of the normal position of the spinal cord in the spinal canal. AJNR Am J Neuroradiol. 1994 ; 15 : 951-9.
 
(2) Miyazaki M, Aoki J, Miyazaki A, et al. Percutaneous radiofrequency ablation of osteoid osteoma using cool-tip electrodes without the cooling system. Jpn J Radiol. 2011 ; 29 : 138-43.
PubMed
(3) Guenetle JP, Lopez MJ, Kim E, et al. Solitary painful osseous metastases : correlation of imaging features with pain palliation after radiofrequency ablation-a multicenter American college of radiology imaging network study. Radiology. 2013 ; 268 : 907-15.
 
(4) Froese G, Das RM, Dunscombe PB. The sensitivity of the thoracolumbar spinal cord of the mouse to hyperthermia. Radiat Res. 1991 ; 125 : 173-80.
PubMed
(5) Yamane T, Tateishi A, Cho S, et al. The effects of hyperthermia on the spinal cord. Spine (Phila Pa 1976). 1992 ; 17 : 1386-91.
PubMed
(6) Dupuy DE, Hong R, Oliver B, et al. Radiofrequency ablation of spinal tumors : temperature distribution in the spinal canal. AJR Am J Roentgenol. 2000 ; 175 : 1263-6.
PubMed
(7) Adachi A, Kaminou T, Ogawa T, et al. Heat distribution in the spinal canal during radiofrequency ablation for vertebral lesions : study in swine. Radiology. 2008 ; 247 : 374-80.
PubMed
(8) Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone : a multicenter study. J Clin Oncol. 2004 ; 22 : 300-6.
 
(9) Nakatsuka A, Yamakado K, Maeda M, et al. Radiofrequency ablation combined with bone cement injection for the treatment of bone malignancies. J Vasc Interv Radiol. 2004 ; 15 : 707-12.
PubMed
(10) Callstrom MR, Atwell TD, Charboneau JW, et al. Painful metastases involving bone : percutaneous image-guided cryoablation-prospective trial interim analysis. Radiology. 2006 ; 241 : 572-80.
PubMed
(11) Nakatsuka A, Yamakado K, Takaki H, et al. Percutaneous radiofrequency ablation of painful spinal tumors adjacent to the spinal cord with real-time monitoring of spinal canal temperature : a prospective study. Cardiovasc Intervent Radiol. 2009 ; 32 : 70-5.
 
(12) Zugaro L, DI Staso M, Gravina GL, et al. Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation : a retrospective study by propensity analysis. Oncol Lett. 2016 ; 11 : 1948-54.
PubMed
P.141 掲載の参考文献
(1) Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005 ; 328 : 679-87.
PubMed
(2) Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994 ; 9 : 745-51.
 
(3) Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer : a randomized, placebo-controlled trial. J Clin Oncol. 2005 ; 23 : 3314-21.
 
(4) Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 ; 98 : 1735-44.
PubMed
(5) Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004 ; 96 : 879-82.
PubMed
(6) Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 ; 21 : 3150-7.
 
(7) Early Breast Cancer Trialists' Collaborative G. Adjuvant bisphosphonate treatment in early breast cancer : meta-analyses of individual patient data from randomised trials. Lancet. 2015 ; 386 : 1353-61.
 
(8) Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX) : a randomised controlled trial. Lancet. 2010 ; 376 : 1989-99.
 
(9) Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 ; 48 : 3082-92.
PubMed
(10) Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss : a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008 ; 34 Suppl 1 : S3-18.
 
(11) Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009 ; 69 : 73-82.
PubMed
(12) Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density : 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008 ; 26 : 1051-7.
PubMed
(13) Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 ; 352 : 154-64.
PubMed
(14) Anagha PP, Sen S. The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer : a systematic review and meta-analysis. J Oncol. 2014 ; 2014 : 625060.
 
(15) Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 ; 26 : 4875-82.
PubMed
(16) Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer : a systematic review and meta-analysis. Oncologist. 2013 ; 18 : 353-61.
PubMed
(17) Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 ; 386 : 433-43.
PubMed
(18) Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 ; 169 : 2008-12.
PubMed
(19) Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 ; 25 : 1038-42.
PubMed
(20) Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 ; 361 : 745-55.
PubMed
(21) Serpa Neto A, Tobias-Machado M, Esteves MA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer : a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012 ; 15 : 36-44.
PubMed
P.147 掲載の参考文献
(1) Yoneda T, Hagino H, Sugimoto T, et al. Antiresorptive agent-related osteonecrosis of the jaw : position paper 2017 of the Japanese allied committee on osteonecrosis of the jaw. J Bone Miner Metab. 2017 ; 35 : 6-19.
 
(2) Taguchi A, Shiraki M, Sugimoto T, et al. Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin. 2016 ; 32 : 1261-8.
PubMed
(3) Hasegawa T, Kawakita A, Ueda N, et al. A multicenter retrospective study of the risk factors associated with medication related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy : can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int. 2017 ; 28 : 2465-73.
 
(4) Owosho AA, Liang STY, Sax AZ, et al. Medication-related osteonecrosis of the jaw : An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 ; 125 : 440-5.
PubMed
(5) 高岡一樹, 岸本裕充. 骨吸収抑制薬関連顎骨壊死 (ARONJ) の現状と今後の課題. 日薬理誌. 2019 ; 153 : 22-7.
Medical*Online
(6) 百合草健圭志. がん歯科支持療法 歯科医師や歯科衛生士が行うがん治療に伴う副作用対策. 日歯医師会誌. 2018 ; 71 : 299-307.
 
(7) 田口明. 骨粗鬆症患者の顎骨壊死-改定ポジションペーパー2016の問題点と新規予防法の効果-. 日整会誌. 2019 ; 93 : 43-9.
Medical*Online
(8) 厚生労働省. 平成28年歯科疾患実態調査結果の概要. https://www.mhlw.go.jp/toukei/list/dl/62-28-02.pdf p.10-21 (2019年6月21日アクセス)
 
(9) 玉岡丈二, 岸本裕充. 【骨粗鬆症治療の現状と展望 2019】骨粗鬆症における口腔管理. Progress in Medicine. 2019 ; 39 : 57-60.
 
(10) 日本乳癌学会, 編. 乳がん診療ガイドライン 1 治療編 2018年版. 第4版. 東京 : 金原出版 ; 2018. p.87-90.
 
P.154 掲載の参考文献
(1) Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover : a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005 ; 90 : 1294-301.
PubMed
(2) Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008 ; 22 : 346-50.
PubMed
(3) Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures : second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014 ; 29 : 1-23.
 
(4) 日本整形外科学会骨粗鬆症委員会. 非定型大腿骨骨折2014年登録調査結果. 日整会誌. 2016 ; 90 : 417-9.
 
(5) Saita Y, Ishijima M, Mogami A, et al. The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Res. 2015 ; 33 : 311-8.
 
(6) Marcano A, Taormina D, Egol KA, et al. Are race and sex associated with the occurrence of atypical femoral fractures? Clin Orthop Relat Res. 2014 ; 472 : 1020-7.
PubMed
(7) Vun SH, Husami Y, Shareef S, et al. Acute nontraumatic clavicle fracture associated with long-term bisphosphonate therapy. Case Rep Orthop. 2014 ; 2014 : 986718.
PubMed
(8) Shimada Y, Ishikawa T, Endo J, et al. Treatment of atypical ulnar fractures associated with long-term bisphosphonate therapy for osteoporosis : autogenous bone graft with internal fixation. Case Rep Orthop. 2017 ; 2017 : 8602573.
PubMed
(9) Gourion-Arsiquaud S, Allen MR, Burr DB, et al. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. 2010 ; 46 : 666-72.
PubMed
(10) Donnelly E, Meredith DS, Nguyen JT, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res. 2012 ; 27 : 672-8.
PubMed
(11) Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010 ; 25 : 2267-94.
 
(12) Capeci CM. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009 ; 91 : 2556-61.
PubMed
P.160 掲載の参考文献
(1) Ishiki H, Iwase S, et al. Prevalence of myofascial pain syndrome in patients with incurable cancer. J Bodyw Mov Ther. 2018 ; 22 : 328-32.
 
P.167 掲載の参考文献
(1) Conley-LaComb MK, Saliganan A, Kandagatla P, et al. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer. 2013 ; 12 : 85.
PubMed
(2) Leblanc R, Lee SC, David M, et al. Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. Blood. 2014 ; 124 : 3141-50.
 
(3) Cotta CV, Konoplev S, Medeiros LJ, et al. Metastatic tumors in bone marrow : histopathology and advances in the biology of the tumor cells and bone marrow environment. Ann Diagn Pathol. 2006 ; 10 : 169-92.
PubMed
(4) Wong KF, Chan JK, Ma SK. Solid tumour with initial presentation in the bone marrow-a clinicopathologic study of 25 adult cases. Hematol Oncol. 1993 ; 11 : 35-42.
PubMed
(5) Al-Muqbel KM. Bone marrow metastasis is an early stage of bone metastasis in breast cancer detected clinically by F18-FDG-PET/CT imaging. Biomed Res Int. 2017 ; 2017 : 9852632.
PubMed
(6) Iguchi H. Recent aspects for disseminated carcinomatosis of the bone marrow associated with gastric cancer : What has been done for the past, and what will be needed in future? World J Gastroenterol. 2015 ; 21 : 12249-60.
 
P.171 掲載の参考文献
(1) Takagi T, Katagiri H, Kim Y, et al. Skeletal metastasis of unknown primary origin at the initial visit : a retrospective analysis of 286 cases. PLoS One. 2015 ; 10 : e0129428.
PubMed
(2) Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012 ; 379 : 1428-35.
PubMed
(3) Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary : from autopsy to microarray. Eur J Cancer. 2007 ; 43 : 2026-36.
PubMed
(4) Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol. 2009 ; 36 : 44-51.
PubMed
(5) Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site : a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013 ; 31 : 217-23.
 
(6) Yoon HH, Foster NR, Meyers JP, et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus : NCCTG N0871 (alliance). Ann Oncol. 2016 ; 27 : 339-44.
PubMed
(7) Moran S, Martinez-Cardus A, Sayols S, et al. Epigenetic profiling to classify cancer of unknown primary : a multicentre, retrospective analysis. Lancet Oncol. 2016 ; 17 : 1386-95.
PubMed
(8) Subbiah IM, Tsimberidou A, Subbiah V, et al. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017 ; 4 : 47-56.
 
(9) Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 ; 373 : 726-36.
PubMed
P.178 掲載の参考文献
(1) 日本整形外科学会, 日本腰痛学会, 監修. 腰痛診療ガイドライン 2019. 改訂2版. 東京 : 南江堂 ; 2019.
 
(2) Jung HS, Jee WH, McCauley TR, et al. Discrimination of metastatic from acute osteoporotic compression spinal fractures with MR imaging. Radiographics. 2003 ; 23 : 179-87.
PubMed
(3) Erly WK, Oh ES, Outwater EK. The utility of in-phase/opposedphase imaging in differentiating malignancy from acute benign compression fractures of the spine. AJNR Am J Neuroradiol. 2006 ; 27 : 1183-8.
PubMed
(4) 矢吹省司, 菊池臣一. 高齢者の膝内側部痛-関節内注射と神経根ブロックによる検討. 臨床整形外科. 1998 ; 33 : 1381-5.
 
P.187 掲載の参考文献
(1) 国立がん研究センター. がん情報サービス : がん登録・統計. https://ganjoho.jp
 
(2) 日本整形外科学会, 日本股関節学会, 編. 変形性股関節症診療ガイドライン2016. 東京 : 南江堂 ; 2016.
 
P.192 掲載の参考文献
(1) Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007 ; 117 : 1137-46.
PubMed
(2) Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis : a systematic review and meta-analysis. Arthritis Rheum. 2012 ; 64 : 523-32.
PubMed
(3) Chang SH, Park JK, Lee YJ, et al. Comparison of cancer incidence among patients with rheumatic disease : a retrospective cohort study. Arthritis Res Ther. 2014 ; 16 : 428.
PubMed
(4) Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015 ; 42 : 564-71.
 
(5) Huang WK, Chiou MJ, Kuo CF, et al. No overall increased risk of cancer in patients with rheumatoid arthritis : a nationwide dynamic cohort study in Taiwan. Rheumatol Int. 2014 ; 34 : 1379-86.
PubMed
(6) Andersen CL, Lindegaard H, Vestergaard H, et al. Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting. Plos One. 2014 ; 9 : e99388.
 
(7) Mercer LK, Davies R, Galloway JB, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford). 2013 ; 52 : 91-8.
PubMed
(8) Lin YC, Chou HW, Tsai WC, et al. The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis : a nationwide retrospective cohort study. Clin Rheumatol. 2015 ; 34 : 1195-202.
PubMed
(9) Liang Y, Yang Z, Qin B, et al. Primary Sjogren's syndrome and malignancy risk : a systematic review and meta-analysis. Ann Rheum Dis. 2014 ; 73 : 1151-6.
 
(10) Mao S, Shen H, Zhang J. Systemic lupus erythematosus and malignancies risk. J Cancer Res Clin Oncol. 2016 ; 142 : 253-62.
 
(11) Wu CY, Chen DY, Shen JL, et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists : a nationwide cohort study. Arthritis Res Ther. 2014 ; 16 : 449.
PubMed
(12) Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma : nationwide population based prospective cohort study from Sweden. BMJ. 2013 ; 346 : f1939.
PubMed
(13) Raaschou P, Soderling J, Turesson C, et al. Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis : a nationwide population-based cohort study. Ann Intern Med. 2018 ; 169 : 291-9.
PubMed
(14) Dreyer L, Cordtz RL, Hansen IMJ, et al. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs : a Danish population-based cohort study. Ann Rheum Dis. 2018 ; 77 : 510-4.
PubMed
(15) Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016 ; 68 : 1-26.
PubMed

ch. 3 がん患者の社会復帰

P.198 掲載の参考文献
(1) 遠藤一司, 坂 英雄. 医療チームによる化学療法の実践. 医療. 2008 ; 62 : 597-9.
Medical*Online
(2) 吉野和穂, 松崎智彦, 有賀直弘, 他. 急性期病院から地域へ. Jpn J Cancer Chemother. 2014 ; 41 (Suppl1) : 1-3.
 
P.203 掲載の参考文献
(2) 厚生労働省. 事業場における治療と職業生活の両立支援のためのガイドライン. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000115267.html
 
() 阿部哲士. がんロコモの展望 整形外科医に知ってほしい「がん相談支援センター」. 整・災外. 2019 ; 62 : 883-6.
 
P.209 掲載の参考文献
(1) 厚生労働省. 疾患を抱える従業員 (がん患者など) の就業継続 現状と課題に関する資料. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/koyou_roudou/koyou/jigyounushi/teichakushien/patient.html
 
(2) Lawton MP, Brody EM. Assessment of older people : self-maintaining and instrumental activities of daily living. Gerontologist. 1969 ; 9 : 179-86.
PubMed
(3) 国立がん研究センターがん対策情報センター. がん患者の就労継続及び職場復帰に資する研究. https://www.ncc.go.jp/jp/cis/divisions/05survivor/05survivor_01.html#5tools
 
(4) 国立がん研究センターがん対策情報センター. がん治療スタッフ向け治療と職業生活の両立支援ガイドブック. https://www.ncc.go.jp/jp/cis/divisions/05survivor/pdf/ryoritsushien_vol1.pdf
 
(5) 城戸顕. 骨転移のがんのリハビリテーション. J Clin Rehabil. 2015 ; 24 : 36-44.
Medical*Online
(6) 城戸顕. 転移性脊椎腫瘍の治療戦略 (8) 「転移性脊椎腫瘍の治療開始の適切なタイミング」. 関節外科. 2015 ; 35 : 65-73.
 
(7) 石田由佳子, 城戸顕. がんのリハビリテーションに必要な知識 5. 骨転移のリスク管理. J Clin Rehabil. 2016 ; 25 : 1200-3.
 

ch. 4 キャンサーボードと骨転移外来

P.215 掲載の参考文献
(1) 厚生労働省ホームページ. がん診療拠点病院等. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/gan/gan_byoin.html
 
(2) 健康局長通知 第0301001号 平成20年3月1日. https://www.mhlw.go.jp/topics/2006/02/tp0201-2.html
 
(3) Cancer Board や院内骨転移登録は骨転移診療に有用か? In : 日本臨床腫瘍学会, 編. 骨転移診療ガイドライン. 東京 : 南江堂 ; 2015. p.17.
 
(4) Shibata H, Kato S, Sekine I, et al. Diagnosis and treatment of bone metastasis : comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open. 2016 ; 1 (2) : e000037. eCollection 2016.
 
P.222 掲載の参考文献
(1) 佐藤信吾, 大川淳. 大学病院でのがん診療に求められる運動器マネジメント. In : ロコモチャレンジ! 推進協議会 がんロコモワーキンググループ. 整形外科医が今日から始めるがんロコモ. 東京 : 総合医学社 ; 2019. p.90-9.
 
(2) 日本臨床腫瘍学会. 骨転移診療ガイドライン. 東京 : 南江堂 ; 2015.
 

書評

最近チェックした商品履歴

Loading...